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Introduction
Tuberculosis kills 1·8 million people per year worldwide. 
Unsuccessful treatment programmes for disease 
control,1,2 and continued transmission3 are contributing 
to the emergence and spread of multidrug-resistant 
(MDR) tuberculosis (ie, bacillary resistance to at least 
rifampicin and isoniazid). The diagnosis and treatment 
of MDR tuberculosis in such settings diverts much 
needed resources away from case ﬁ nding and the 
treatment of drug-susceptible tuberculosis. Extensively 
drug-resistant (XDR) tuberculosis (ie, bacillary resistance 
to at least rifampicin, isoniazid, a ﬂ uoroquinolone, and 
at least one second-line injectable drug—amikacin, 
kanamycin, or capreomycin) has been identiﬁ ed in more 
than 59 countries and, because of the changes in 
international travel and migration patterns, the threat is 
global.4 Treatment of XDR tuberculosis shows varying 
results.5–8 Data from Estonia suggested that the outcome 
associated with resistance to capreomycin was poor.8,9 
However, data from Peru, although few, are encouraging 
because 60% of patients with XDR tuberculosis 
completed treatment or were cured with intensive 
multidrug treatment.10
However, despite having the highest caseload of 
tuberculosis, there have been few reports of XDR 
tuberculosis from high-burden settings, including those 
with a high prevalence of HIV/AIDS, possibly because of 
the absence of comprehensive drug-susceptibility testing. 
Reports from KwaZulu Natal, South Africa, showed that 
almost all patients with XDR tuberculosis acquired in a 
hospital or community outbreak were infected with HIV 
and had a short-term mortality rate of more than 80%.11,12 
Because of the initial global media scare, XDR tuberculosis 
in Africa is generally perceived to arise predominantly in 
HIV-infected patients, who have increased susceptibility 
to infection and poor survival. Subsequently, 4% of cases 
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Summary
Background Data from Kwazulu Natal, South Africa, suggest that almost all patients with extensively drug-resistant 
(XDR) tuberculosis are HIV-positive, with a fatal outcome. Since, there are few data for the treatment-related outcomes 
of XDR tuberculosis in settings with a high HIV prevalence, we investigated the associations of these diseases in such 
settings to formulate recommendations for control programmes.
Methods In a retrospective cohort study, we analysed the case records of patients (>16 years old) with XDR tuberculosis 
(culture-proven at diagnosis) between August, 2002, and February, 2008, at four designated provincial treatment 
facilities in South Africa. We used Cox proportional hazards regression models to assess risk factors associated with 
the outcomes—mortality and culture conversion.
Findings 195 of 227 patients were analysed. 21 died before initiation of any treatment, and 174 patients (82 with HIV 
infection) were treated. 62 (36%) of these patients died during follow-up. The number of deaths was not signiﬁ cantly 
diﬀ erent in patients with or without HIV infection: 34 (41%) of 82 versus 28 (30%) of 92 (p=0·13). Treatment with 
moxiﬂ oxacin (hazard ratio 0·11, 95% CI 0·01–0·82; p=0·03), previous culture-proven multidrug-resistant tuberculosis 
(5·21, 1·93–14·1; p=0·001), and number of drugs used in a regimen (0·59, 0·45–0·78, p<0·0001) were independent 
predictors of death. Fewer deaths occurred in patients with HIV infection given highly active antiretroviral therapy 
than in those who were not (0·38, 0·18–0·80; p=0·01). 33 (19%) of 174 patients showed culture conversion, of which 
23 (70%) converted within 6 months of initiation of treatment.
Interpretation In South Africa, patients with XDR tuberculosis, a substantial proportion of whom are not infected 
with HIV, have poor management outcomes. Nevertheless, survival in patients with HIV infection is better than 
previously reported. The priorities for the country are still prevention of XDR tuberculosis, and early detection and 
management of multidrug-resistant and XDR tuberculosis through strengthened programmes and laboratory 
capacity.
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of MDR tuberculosis were in fact shown to be cases of 
XDR disease, and were present in most provinces in 
South Africa.13,14
Thus, the high rate of HIV infection and poorly 
functioning tuberculosis control programmes in many 
parts of Africa are likely to contribute to the emergence of 
XDR tuberculosis, which could destablise the control of 
tuberculosis in these areas.15 Urgent implementation of 
rational control policies is required to counter this threat. 
However, there are few data from Africa on which to base 
such recommendations, including those relevant to 
advocacy, diagnosis, case ﬁ nding, and treatment. Further-
more, several uncertainties have implications for the 
design and implementation of tuberculosis control 
programmes, including the prognosis for individuals with 
XDR tuberculosis with or without HIV infection in a non-
outbreak setting, the eﬀ ect of highly active antiretroviral 
therapy on outcome in patients with HIV infection, the 
best treatment regimens for XDR tuberculosis, and 
predictors of poor outcome in a resource-poor setting. We 
therefore attempted to address these issues on the basis of 
our experience of treating patients with XDR tuberculosis 
at several centres in South Africa.
Methods
Study setting and participants
We retrospectively reviewed the case records of 
227 patients (>16 years) with XDR tuberculosis, diagnosed 
(culture proven) between August, 2002, and February, 
2008, at four of nine dedicated provincial facilities for the 
treatment of XDR tuberculosis in South Africa. This 
country has a population of nearly 48 million people, 
HIV prevalence of 11% in 2008, tuberculosis notiﬁ cation 
of 948 per 100 000 population in 2007, and notiﬁ cation of 
more than 7000 cases of MDR disease in 2007. National 
policy recommends that drug-susceptibility testing 
should be done for rifampicin, isoniazid, and ethambutol 
in all new cases of tuberculosis who have not culture-
converted by 3 months, all retreatment cases at 
presentation, and high-risk patients. Second-line testing 
was done by use of the indirect method on solid media 
(Middlebrook 7H11, Becton Dickinson, Le Pont de Claix, 
France) at dedicated provincial tuberculosis laboratories 
(Cape Town, Port Elizabeth, Kimberley, and Johannesburg) 
with standardised reagents and methods, which did not 
change during the study. Ethical approval was obtained 
from the University of Cape Town, South African Medical 
Research Council, and the University of Witwatersrand‘s 
human research ethics committees.
Diagnosis of XDR tuberculosis
According to national policy, isolates resistant to isoniazid 
and rifampicin should be sent for second-line testing 
(ethionamide, oﬂ oxacin, amikacin, and streptomycin in 
selected centres). Patients with MDR tuberculosis who 
were still culture-positive at the end of the intensive phase 
of treatment were also sent for second-line testing. In this 
study, patients with isolates of Mycobacterium tuberculosis 
that were resistant at diagnosis (time of sputum collection) 
to at least isoniazid, rifampicin, a ﬂ uoroquinolone, and at 
least one of the second-line injectable drugs (amikacin, 
kanamycin, or capreomycin) were judged to have XDR 
tuberculosis. In early 2007, with the newly adopted 
deﬁ nition of XDR tuberculosis and revised guidelines, 
second-line drug-susceptibility testing again became 
widely available. Thus, XDR tuberculosis was only widely 
diagnosed and treated from late 2006 and early 2007, with 
a few cases identiﬁ ed retrospectively from before this 
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Figure 1: Study proﬁ le (A), and timeline for data gathering stratiﬁ ed by 
recruitment institution (B)
MDR=multidrug-resistant. XDR=extensively drug-resistant. *Local approval was 
only obtained for this period.
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period. Drug-susceptibility testing to capreo mycin, 
cycloserine, terizidone (a derivative containing a double 
molecule of cycloserine), and ﬂ uoroquinolones other than 
oﬂ oxacin is not available within the provincial laboratories. 
However, to gain further insight into prevailing patterns, 
we tested the susceptibility to capreomycin in 57 isolates 
obtained from patients in Western Cape in accordance 
with the guidelines of the Centers for Disease Control 
and Prevention.16
Treatment regimens
MDR tuberculosis, was generally treated with a standard-
ised regimen of kanamycin, oﬂ oxacin, ethiona mide, 
ethambutol, and pyrazinamide (terizidone was added for 
ethambutol-resistant patients) before the diagnosis of 
XDR tuberculosis. By contrast, treatment of XDR disease 
was given in hospital, and individualised with the use of 
capreomycin and para-aminosalicylic acid as the main 
drugs, with other ﬁ rst-line and second-line drugs used at 
Mortality status Sputum-culture conversion
Alive Died p value Yes No p value
Patients 112 (64%) 62 (36%) ·· 33 (19%) 141 (81%) ··
Age (years; median, IQR) 32·1 (25·8–42·8) 37·2 (28·5–47·1) 0·07 33·2 (26·3–044·7) 33·4 (26·3–44·4) 0·99
HIV status ·· ·· 0·13 ·· ·· 0·83
Positive 48 (43%) 34 (55%) ·· 15 (45%) 67 (48%) ··
Negative 64 (57%) 28 (45%) ·· 18 (55%) 74 (52%) ··
Sex ·· ·· 0·59 ·· ·· 0·47
Female 59 (53%) 30 (48%) ·· 15 (45%) 67 (48%) ··
Male 53 (47%) 32 (52%) ·· 18 (55%) 74 (52%) ··
Ethnic origin ·· ·· 0·37 ·· ·· 0·11
Black 63 (56%) 41 (66%) ·· 20 (61%) 84 (60%) ··
Mixed 48 (43%) 21 (34%) ·· 12 (36%) 57 (40%) ··
White 1 (0·9%) 0 ·· 1 (3%) 0 ··
Smoking history ·· ·· 0·004 ·· ·· 0·10
Yes 39 (35%) 10 (16%) ·· 9 (27%) 40 (28%) ··
No 34 (30%) 15 (24%) ·· 14 (42%) 35 (25%) ··
Unknown 39 (35%) 37 (60%) ·· 10 (30%) 66 (47%) ··
Previous multidrug-resistant 
tuberculosis
·· ·· <0·0001 ·· ·· 0·11
Yes 70 (63%) 55 (89%) ·· 20 (61%) 105 (74%) ··
No 42 (38%) 7 (11%) ·· 13 (39%) 36 (26%) ··
Weight (kg; median, IQR; n=65) 50·0 (44·0–60·0) 44·0 (39·0–49·0) 0·004 54·5 (49·8–61·3) 48·0 (39·0–52·5) 0·007
Drugs used ·· ·· ·· ·· ·· ··
Oﬂ oxacin ·· ·· 0·02 ·· ·· 0·50
Yes 25 (22%) 5 (8%) ·· 7 (21%) 23 (16%) ··
No 87 (78%) 57 (92%) ·· 26 (79%) 118 (84%) ··
Capreomycin ·· ·· 0·43 ·· ·· 0·33
Yes 103 (92%) 58 (94%) ·· 32 (97%) 130 (92%) ··
No 9 (8%) 3 (5%) ·· 1 (3%) 11 (8%) ··
Ethionamide ·· ·· 0·61 ·· ·· 0·72
Yes 66 (59%) 39 (63%) ·· 19 (58%) 86 (61%) ··
No 46 (41%) 23 (37%) ·· 14 (42%) 55 (39%) ··
Ethambutol ·· ·· 0·01 ·· ·· 0·40
Yes 57 (51%) 44 (71%) ·· 14 (42%) 87 (62%) ··
No 55 (49%) 18 (29%) ·· 19 (58%) 54 (38%) ··
Para-aminosalicylic acid ·· ·· 0·41 ·· ·· 0·13
Yes 102 (91%) 54 (87%) ·· 32 (97%) 124 (88%) ··
No 10 (9%) 8 (13%) ·· 1 (3%) 17 (12%) ··
Moxiﬂ oxacin ·· ·· 0·02 ·· ·· 0·24
Yes 13 (12%) 1 (2%) ·· 1 (3%) 13 (9%) ··
No 99 (88%) 61 (98%) ·· 32 (97%) 128 (91%) ··
Data are number (%), unless otherwise indicated.
Table 1: Sociodemographic and clinical characteristics according to outcomes in 174 patients with extensively drug-resistant tuberculosis
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the discretion of the attending clinician, or to which the 
microorganism showed susceptibility. Capreomycin and 
para-aminosalicylic acid were introduced into the 
programme in about March, 2007. Linezolid is unavailable 
through the national tuberculosis programme and 
moxiﬂ oxacin is only accessible at speciﬁ c centres (in 
Eastern Cape) or on a restricted basis through non-
governmental organisations (eg, in Western Cape). 
Highly active antiretroviral therapy was oﬀ ered to all 
patients infected with HIV at the discretion of the 
attending physician.
Outcomes
The date of diagnosis of XDR tuberculosis was the same 
as the date on which the sputum sample was sent to the 
laboratory, and from which the organism was cultured. 
There was thus a delay between diagnosis and initiation of 
treatment. Conversion was judged to have occurred when 
two consecutively negative cultures were obtained, 
1 month apart, and when the ﬁ rst culture was positive at 
the start of treatment for XDR tuberculosis. Because 
widespread and targeted screening for XDR tuberculosis 
was only available in many centres from late 2006 or early 
2007, most of the cohort had a short follow-up. Hence, we 
focused on early outcomes (conversion and mortality).
Strain typing
To establish whether XDR tuberculosis was acquired or 
transmitted, a subset of isolates (n=52) from patients 
living in the Western Cape were genotyped by use of 
IS6110 DNA ﬁ ngerprinting,17 spoligotyping,18 and DNA 
sequencing of the inhA promoter and the katG, rpoB, 
embB, pncA, gyrA, and rrs genes. Transmission chains 
were deﬁ ned by use of isolates that had identical IS6110 
DNA ﬁ ngerprints, spoligotypes, and mutations that 
conferred resistance.
Statistical analysis
A risk-management strategy for data, including double 
data entry, was used to ensure data integrity. We 
compared categorical variables by use of the χ² test, or 
Fisher’s exact test when appropriate, and we compared 
continuous variables, because of the non-normal 
distribution of the analysed variables, using the 
Mann-Whitney U test or Kruskal-Wallis non-parametric 
test. The Kaplan-Meier method was used to calculate 
probabilities of events at diﬀ erent timepoints, and the 
log-rank test was used to compare these probabilities by 
group. Cox proportional hazards regression models 
were ﬁ tted to determine risk factors associated with 
outcomes in time-to-event-based analyses. Variables 
that were signiﬁ cantly associated with the outcome 
(p<0·05) were included in the ﬁ nal model. The 
proportionality assumption of the Cox models was 
tested with –ln(–ln [survival]) curves and regression of 
scaled Schoenfeld residuals on functions of time. The 
assumption of uninformative censoring (ie, more 
censored observations at an earlier time in one group 
than in another group, or a greater proportion of 
censored survival times in patients with a particular 
range of values of the explanatory variables) was 
investigated with observed survival times plotted 
against the values of the explanatory variables included 
in the model. Additionally, sensitivity analyses were 
done to account for patients excluded from the analysis, 
and for those lost to follow-up.
Role of the funding source
None of the funding sources had any role in the design 
or execution of the study. The corresponding author in 
consultation with the other lead authors had ﬁ nal 
decision to submit this work for publication. All authors 
had access to all the data.
Results
Figure 1A shows a summary of the study plan. 199 of 
227 enrolled patients were included in the further analysis 
(ﬁ gure 1A). All patients diagnosed with XDR tuberculosis 
were admitted to the facility until conversion of the 
sputum smear. Figure 1B shows the centre-speciﬁ c dates 
of enrolment (Feb 1, 2008, was the enrolment censor date 
and Sept 1, 2008, was the follow-up censor date).
In the ﬁ nal analyses, the 174 patients started on 
treatment for XDR tuberculosis were young (median age 
33 years, IQR 26–45), mainly of mixed ethnic origin, and 
82 (47%) were infected and 92 (53%) were not infected 
Patients given drug Treatment duration 
(months; median, IQR)
Resistance pattern (number of 
patients resistant to 
treatment/number of 
susceptibility tests done in 
treated patients [%])
Ethambutol 103 (59%) 6·8 (4·0–11·4) 62/117 (53%)
Pyrazinamide 140 (80%) 7·2 (3·3–11·5) ND
Amikacin 3 (2%) 4·2 (2·1–5·8) 124/124 (100%)
Capreomycin 162 (93%) 7·2 (3·1–12·1) 22/42 (52%)
Kanamycin 4 (2%) 13·4 (4·8–15·6) 50/50 (100%)
Moxiﬂ oxacin 14 (8%) 12·1 (10·4–18·3) ND
Oﬂ oxacin 31 (18%) 8·1 (4·2–12·0) 174/174 (100%)
Terizidone 147 (84%) 9·2 (3·5–12·1) ND
Ethionamide 107 (61%) 8·0 (3·2–11·9) 59/167 (35%)
Para-aminosalicylic acid 156 (90%) 7·3 (3·7–12·2) ND
Amoxicillin–clavulanate 66 (38%) 7·1 (3·1–12·2) ND
Clarithromycin 77 (44%) 8·6 (3·7–13·9) ND
Clofazimine 28 (16%) 8·7 (4·3–14·3) ND
Dapsone 95 (55%) 6·6 (3·1–11·6) ND
Azithromycin 11 (6%) 7·9 (2·8–12·1) ND
Isoniazid+thiacetazone 2 (1%) 7·8 (1·9–13·7) ND
Rifabutin 1 (<1%) NA ND
Streptomycin 1 (<1%) NA ND
Data are number (%), unless otherwise indicated. ND=not done. NA=not applicable.
Table 2: Drugs used in treatment regimens for patients (n=174) with extensively drug-resistant tuberculosis
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with HIV. Table 1 shows the demographic variables 
stratiﬁ ed by mortality and conversion status. There was 
no diﬀ erence in the number of deaths or sputum-culture 
conversions (p>0·05) when these outcomes were 
stratiﬁ ed by sex, ethnic origin, and the number of 
previous episodes of MDR tuberculosis (median 1 episode 
[1–1] each in those who survived and died, 1 episode [1–2] 
in those who converted, and 1 episode [1–2] in those who 
did not convert). There was no signiﬁ cant diﬀ erence in 
the duration of previous treatment for MDR tuberculosis 
in patients who survived versus those who died (median 
8·0 months [5·0–12·0] vs 5·5 months [4–8], respectively; 
p=0·7), and converters versus non-converters (9 months 
[6–14] vs 6 months [4–10], respectively; p=0·37). Similarly, 
the median number of previous drug-susceptible 
episodes of tuberculosis in the same groups was not 
diﬀ erent (survivors vs non-survivors: 1 [1–2] vs 1 [1–2], 
respectively, p=0·1; converters vs non-converters: 1 [1–2] 
vs 1 [1–2], respectively, p=0·2). The time from sputum 
acquisition to start of treatment was signiﬁ cantly longer 
in those who survived than in those who died (78 days 
[53–107] vs 57 days [36–67]; p=0·001), and in converters 
than in non-converters (91 days [61–116] vs 59 days [43–86], 
respectively; p=0·001). The median duration of follow-up 
from the start of treatment to event (death, loss to follow-
up, or the date of censor) was 6·9 months (3·1–12·0).
72% of patients with XDR tuberculosis had previous 
culture-conﬁ rmed MDR tuberculosis (table 1), suggesting 
acquisition of additional resistance during this treatment. 
17 patients with XDR tuberculosis had an isolate of 
M tuberculosis with a unique IS6110 genotype, whereas 
the remaining 35 patients had an isolate that could be 
genotypically grouped into one of six clusters. Ten (19%) 
of these clustered cases showed mutations that caused 
identical resistance to ﬁ rst-line and second-line drugs, 
suggesting that resistance to second-line drugs was 
acquired in 81% of patients from the Western Cape.
174 patients started treatment with a regimen containing 
capreomycin and para-aminosalicylic acid, and were given 
a median of seven drugs per regimen (IQR 6–8). The 
drug-speciﬁ c resistance and treatment proﬁ le are 
summarised in table 2. Median duration of treatment was 
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Figure 2: Kaplan-Meier estimates of culture-conversion and deaths in patients with extensively drug-resistant tuberculosis
(A) Probabilities of culture conversion in patients with and without HIV infection given treatment; (B) probabilities of death in patients who died before initiation 
of treatment stratiﬁ ed by HIV status; (C) probabilities of death in patients with and without HIV infection given treatment from date of treatment initiation; 
and (D) probabilities of death in patients with HIV infection given treatment stratiﬁ ed according to use of highly active antiretroviral therapy.
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6·9 months (3·1–12·0), and duration of treatment with 
injectable drugs was 13·4 months (4·7–15·5). 33 (58%) of 
57 random isolates that were retrospectively tested for 
susceptibility to capreomycin were resistant, and 42 (74%) 
patients were given the drug after the isolate was harvested 
for susceptibility testing. Only 20 (48%) of these patients 
had isolates that were capreomycin-susceptible. In the 
resistant versus susceptible group, there was no signiﬁ cant 
diﬀ erence in the number of patients who converted (six 
[27%] of 22 vs three [15%] of 20; p=0·33) or died (seven 
[32%] of 22 vs six [30%] of 20; p=0·9). Overall drug 
susceptibility proﬁ les did not diﬀ er with HIV status or 
when HIV-infected patients were stratiﬁ ed by CD4-cell 
count. 52 (63%) of 82 patients with HIV infection given 
treatment for XDR tuberculosis were also taking highly 
active antiretroviral therapy; zidovudine, lamivudine, and 
efavirenz were the most commonly used antiretroviral 
drugs in 26 (50%) of these patients.
Initiation of treatment resulted in culture conversion 
in 33 (19%) of 174 patients (table 1), and the probability of 
culture conversion did not diﬀ er by HIV status (ﬁ gure 2A). 
23 (70%) of these patients converted by 6 months, 
28 (85%) by 9 months, and 30 (91%) by 12 months. Before 
the date for censor follow-up (Sept 30, 2008), two (6%) of 
33 patients with XDR tuberculosis who had converted 
had reverted back to culture-positive status. In a univariate 
Cox regression analysis, low weight (<50 kg) before 
treatment was associated with conversion failure (hazard 
ratio 3·31, 95% CI 1·08–10·1; p=0·04).
The cause of death could not be ascertained for the 
21 patients who died before the start of treatment for 
XDR tuberculosis, but the proportion of deaths in 
patients with HIV infection was signiﬁ cantly higher than 
in the uninfected patients in the time-to-event analysis 
(ﬁ gure 2B). 195 of 227 enrolled patients with XDR 
tuberculosis were analysed for the mortality outcome. 
62 (36%) of 174 died during follow-up. Numbers of deaths 
in patients with or without HIV infection were not 
signiﬁ cantly diﬀ erent: 34 (41%) of 82 versus 28 (30%) of 
92 (p=0·13; table 1). Additionally, the probability of 
survival did not diﬀ er in the two groups (ﬁ gure 2C).
In the Cox multivariate model, treatment with moxi-
ﬂ oxacin and increasing number of drugs used in a regimen 
were independent predictors of a reduction in the number 
of deaths, whereas previous culture-proven MDR 
tuberculosis was an independent predictor of death 
(table 3). Survival did not diﬀ er with CD4-cell count (data 
not shown), but the analysis was based on a small number 
of participants with veriﬁ able CD4-cell counts at the time 
of initiation of treatment (35 of 82 patients; median 
CD4-cell count 273 cells per mm³ [IQR 169–396]). Results 
for survival were similar when the date of diagnosis rather 
than the date of treatment initiation was used, and 
outcomes (mortality and culture conversion) were similar 
before and after March, 2007, when capreomycin and para-
aminosalicylic acid were introduced into the programme 
(data not shown). In a sub-analysis of patients with HIV 
infection, only highly antiretroviral therapy and 
moxiﬂ oxacin were independent predictors of survival 
(table 3). Signiﬁ cantly fewer individuals with HIV infection 
given highly antiretroviral therapy died than did those not 
given this therapy (table 3), and number of deaths at 
12 months was 13 (25%) of 52 versus 19 (66%) of 
29 (ﬁ gure 2D), respectively. The median CD4-cell counts in 
patients taking highly antiretroviral therapy were 267 per 
mm³ (160–365) versus 440 per mm³ (170–477) in those not 
taking this therapy. A formal test of the assumptions of the 
proportional hazards, and of uninformative censoring, 
indicated that these assumptions were not violated.
Case records from three treatment centres (Western 
Cape, Northern Cape, and Gauteng) were com-
prehensively reviewed for adverse drug reactions, which 
were reported in 67 (58%) of 115 patients. Table 4 shows 
the drug-speciﬁ c adverse eﬀ ects. 58 (36%) of 161 adverse 
drug reactions required no intervention; 69 (43%) needed 
modiﬁ cation in the duration of treatment or frequency 
of administration of the drug, or prescription of an 
additional drug to treat the adverse event; the drug 
causing the adverse reaction was stopped in 26 (16%) 
reactions; and six (4%) patients died (ﬁ ve with rapidly 
deteriorating renal failure and one with hypokalaemia) 
at a median of 14 days (IQR 9–73) after starting 
capreomycin. Highly active antiretroviral therapy was 
generally well tolerated.
Univariate analysis Multivariate analysis
Hazard ratio 
(95% CI)
p value* Hazard ratio 
(95% CI)
p value
All patients (n=174)
Isoniazid 0·20 (0·08–0·49) <0·0001 0·76 (0·24–2·51) 0·68
Moxiﬂ oxacin 0·12 (0·02–0·89) 0·03 0·11 (0·01–0·82) 0·03
Ethambutol 1·87 (1·08–3·26) 0·03 1·49 (0·69–3·23) 0·31
Dapsone 2·19 (1·25–3·84) 0·006 1·79 (0·84–3·85) 0·13
Clofazamine 0·30 (0·11–0·82) 0·02 0·54 (0·14–2·08) 0·37
Clarithromycin 0·55 (0·32–0·94) 0·03 1·46 (0·61–3·52) 0·40
Terizidone 0·48 (0·27–0·84) 0·01 1·35 (0·71–2·55) 0·37
Number of drugs used 0·74 (0·61–0·88) 0·001 0·59 (0·45–0·78) <0·0001
Previous treatment for multidrug-
resistant tuberculosis
3·73 (1·69–8·22) 0·001 5·21 (1·93–14·1) 0·001
HIV-infected patients (n=82)
Highly active antiretroviral therapy 0·31 (0·15–0·61) 0·001 0·38 (0·18–0·80) 0·01
Isoniazid 0·17 (0·05–0·56) 0·005 0·41 (0·06–2·96) 0·39
Moxiﬂ oxacin 13·00 (0·02–0·92) 0·006 0·08 (0·01–0·61) 0·02
Pyrazinamide 4·10 (1·00–17·50) 0·04 3·48 (0·74–16·50) 0·12
Clofazamine 0·21 (0·05–0·86) 0·03 1·37 (0·14–13·82) 0·79
Number of drugs used 0·74 (0·56–0·99) 0·04 0·87 (0·58–1·26) 0·43
Previous treatment for multidrug-
resistant tuberculosis
7·46 (1·79–31·20) 0·006 4·50 (0·83–24·40) 0·08
*Wald test. Oﬂ oxacin not included because it was signiﬁ cant in the χ2 test (p=0·02), but not in the time-to-event 
analysis with Cox regression model (p>0·05).
Table 3: Cox proportional hazards regression model of factors associated with risk of death in all patients 
given treatment for extensively drug-resistant tuberculosis, and in HIV-infected patients only
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Ten (7%) of 135 patients with XDR tuberculosis were 
assessed for surgery at a centre with facilities for thoracic 
surgery. Four of these patients refused surgery, three 
were judged to be unsuitable for surgery, and three 
underwent the procedure (two pneumonectomies and 
one lobectomy). One of the patients who had surgery 
converted and continued treatment but later relapsed, 
the other two died 12 days and 24 days after surgery. Four 
patients with XDR tuberculosis had previously undergone 
surgery for MDR tuberculosis.
Discussion
We have shown several associations of XDR tuberculosis 
in settings with high HIV prevalence. First, XDR 
tuberculosis in South Africa is not predominantly 
associated with HIV infection as perceived from studies 
done in KwaZulu Natal in 2006 and 2009.11,12 Although the 
numbers of deaths were high, we noted no diﬀ erence in 
treatment outcomes (mortality and culture-conversion 
status) when comparing patients who were HIV-positive 
with those who were HIV-negative. This ﬁ nding is 
important for the design of policy guidelines and 
programmes for management, reduction of stigma 
associated with a fatal prognosis, and advocacy purposes. 
Second, fewer deaths occurred in patients with 
concomitant HIV infection and XDR tuberculosis given 
highly antiretroviral therapy than in untreated patients. 
These data also have implications for the design of 
programmes for the treatment of XDR tuberculosis since 
the data from the studies in KwaZulu Natal indicated an 
invariably fatal outcome in individuals with concomitant 
HIV infection, showing the importance of WHO’s 
recommended strategy for treatment of HIV/AIDS and 
tuberculosis.19 Third, that moxiﬂ oxacin was an independent 
predictor of survival is another useful ﬁ nding because 
there are no new licensed drug options for XDR 
tuberculosis in high-burden settings. Fourth, previous 
culture-proven MDR tuberculosis, and high number of 
drugs used in a regimen were predictors of survival and 
culture conversion. Fifth, the outcome of management of 
patients with XDR tuberculosis in South Africa is poor, 
despite good adherence and availability of drugs.
Our results are relevant to African governments and 
the WHO Stop TB Partnership to improve management 
guidelines for XDR tuberculosis programmes, case 
ﬁ nding, diagnostic algorithms, and outcomes of 
treatment in patients with and without HIV infection in 
resource-limited settings.
Reactions No action taken* Change in dose or 
frequency*
Implicated drug 
stopped*
Life threatening* Death*
Nausea or vomiting 35 (22%) 9 (26%) 16 (46%) 10 (29%) 0 0
Diarrhoea 22 (14%) 3 (14%) 17 (77%) 2 (9%) 0 0
Other gastrointestinal symptoms 
(abdominal pain, dyspepsia, epigastric 
discomfort, cramps)
22 (14%) 11 (50%) 8 (36%) 3 (14%) 0 0
Dizziness, disorientation, or confusion 13 (8%) 13 (100%) 0 0 0 0
Loss of hearing 10 (6%) 5 (50%) 2 (20%) 3 (30%) 0 0
Renal failure† 7 (4%) 0 0 0 2 (28%) 5 (71%)
Body aches or pains 10 (6%) 6 (60%) 3 (30%) 1 (10%) 0 0
Headache 8 (5%) 4 (50%) 4 (50%) 0 0 0
Skin reaction 7 (4%) 2 (29%) 5 (71%) 0 0 0
Hypokalaemia 7 (4%) 1 (14%) 4 (57%) 1 (14%)‡ 0 1 (14%)§
Hypothyroidism 6 (4%) 0 5 (83%) 1 (17%) 0 0
Depression 2 (1%) 1 (50%) 0 1 (50%) 0 0
Sore tongue or throat 2 (1%) 0 2 (100%) 0 0 0
Numbness of extremities 2 (1%) 0 0 2 (100%) 0 0
Generalised itchiness 2 (1%) 1 (50%) 1 (50%) 0 0 0
Psychosis 1 (<1%) 0 0 1 (100%) 0 0
Renal impairment 1 (<1%) 0 0 1 (100%) 0 0
Fatigue 1 (<1%) 1 (100%) 0 0 0 0
Visual disturbance 1 (<1%) 1 (100%) 0 0 0 0
Thrombophlebitis 1 (<1%) 0 1 (100%) 0 0 0
Arthralgia 1 (<1%) 0 1 (100%) 0 0 0
Total 161 (100%) 58 (36%) 69 (43%) 26 (16%) 2 (1%) 6 (4%)
Data are number (%). *Proportion of speciﬁ c adverse drug reactions. †Creatinine concentration greater than six times the upper limits of normal. ‡Potassium concentration 
2·0–2·4 mmol/L. §Potassium concentration less than 2·0 mmol/L.
Table 4: Adverse drug reactions (n=161) in 67 of 115 patients from the Western Cape, Northern Cape, and Gauteng provinces started on treatment for 
extensively drug-resistant tuberculosis
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Another important ﬁ nding was that overall prognosis 
for the patient was poor irrespective of HIV status, and 
despite supervised inpatient multidrug treatment and 
access, when available, to surgical resection of diseased 
lung. Indeed, conversion rates were low (19%) and 
culture reversion occurred in some patients (6% by end 
of study and, at the time of writing, 54% of 13 converters 
in Western Cape for whom we have follow-up data after 
the study). Moreover, the overall 12-month mortality rate 
was higher than the rates associated with most aggressive 
malignant diseases. By contrast, results from four 
studies in intermediate or high-burden settings, with 
smaller cohorts, were better than our results.7,10,20,21 
Mitnick and colleagues10 in Peru showed that 32 (67%) of 
48 patients with XDR tuberculosis in the cohort had 
converted by 4 months (median time to conversion 
90 days), and 11 (23%) died. Possible reasons for the 
poorer survival in our cohort of patients, independent of 
HIV status, include the long duration of drug-resistant 
and drug-susceptible tuberculosis before initiation of 
treatment for XDR tuberculosis; delays in initiation of 
such treatment; malnutrition; co-exposures such as 
smoking, alcohol, and illicit drug use; diﬀ erent 
M tuberculosis strains (their pathogenic characteristics 
and resistance patterns); lack of treatment with 
moxiﬂ oxacin; and exposure to helminths and other 
environmental mycobacteria, which might alter the 
underlying immunological phenotype,22 thus reducing 
eﬀ ectiveness of treatment. Other causes such as 
malabsorption of drugs, and interactions between 
antituberculosis drugs and highly active antiretroviral 
therapy seem unlikely as putative causes because of 
similar outcomes in patients with or without HIV 
infection, and because highly active antiretroviral therapy 
was well tolerated. The poor outcomes draw attention to 
the need to urgently develop and prospectively validate 
new interventions for XDR tuberculosis.23 The outcome 
data and the high proportion of acquired resistance to 
second-line drugs in this study and nationally13,24 suggest 
that the national tuberculosis control programmes need 
to aggressively ensure treatment adherence with eﬀ ective 
regimens to restrict the spread of resistance. This 
prevention of drug resistance can be achieved by 
programme strengthening to prevent system failures,25,26 
integration of treatment for drug-resistant tuberculosis 
and HIV/AIDS,27 intensive counselling and follow-up, 
and surgery when necessary and available.
Available data for XDR tuberculosis from Africa indicate 
that this disease was almost exclusively associated with 
HIV infection, and that prognosis in patients with both 
diseases is poor with a high 30-day mortality rate.11,12 Hence, 
since the data were ﬁ rst reported in 2006, and again in 
2009 from Kwazulu Natal, the general opinion is that XDR 
tuberculosis in Africa arises predominantly in HIV-infected 
individuals who have increased suscep tibility to 
tuberculosis.28 By contrast, our data show that a substantial 
proportion (53%) of patients with XDR tuberculosis 
outside the KwaZulu Natal province are HIV-negative. 
Moreover, survival in patients with HIV infection in our 
study cohort, from a wider South African setting, is 
substantially longer (50% died at 12 months vs 83–100% in 
KwaZulu Natal11,12). Although not small, this proportion is 
substantially better than in KwaZulu Natal.11,12 The reasons 
are unclear but might include patients presenting at 
diﬀ erent stages of their illness, degree of immuno-
suppression, diﬀ erent drug-susceptibility proﬁ les of 
isolates, lack of availability of capreomycin before 2006, 
nutritional status, and local diﬀ erences in strain virulence. 
Furthermore, the KwaZulu Natal strain showed diﬀ erent 
pathogenic properties due to its high capacity to cause 
recrudescence through reinfection, and clonal expansion 
through transmission compared with the ﬁ ndings in the 
Western Cape, where resistance was mostly acquired.29,30 
We also show that highly active antiretroviral therapy, 
despite its overlapping toxicity and adverse eﬀ ects with 
antituberculosis drugs, and the high pill burden, 
substantially improves survival in patients with 
concomitant HIV/AIDS and XDR tuberculosis, and was 
generally well tolerated. Our data suggest that highly active 
antiretroviral therapy should be used at an early stage in 
patients with HIV infection and XDR tuberculosis. These 
ﬁ ndings are important for advocacy purposes because they 
support the notion that treatment for XDR tuberculosis in 
patients with HIV infection is not without hope, and thus 
counteract the stigmatisation of this group of patients.
Treatment with moxiﬂ oxacin was an independent 
predictor of survival in oﬂ oxacin-resistant patients with 
XDR tuberculosis and has hitherto not been described. 
Evidence suggests that the incomplete cross-resistance 
within the quinolone class can be explained by diﬀ erential 
drug-speciﬁ c binding to DNA gyrase.31 Unlike the cohort 
in Mitnick and colleagues’ study,10 with 34 (72%) of 
47 patients ever treated with moxiﬂ oxacin, our programme 
does not provide this drug nationally. Prospective clinical 
and in-vitro studies are urgently needed to investigate 
how best to use ﬂ uoroquinolones for treatment of XDR 
tuberculosis. Meanwhile, we recommend that, in the 
absence of speciﬁ c results of drug-susceptibility testing, 
moxiﬂ oxacin should be used in treatment regimens for 
XDR tuberculosis unless contraindicated. With our 
ﬁ ndings and those from studies of MDR tuberculosis,32,33 
we also suggest that patients with a weight of less than 
50 kg should be given nutritional supplementation, 
intensive follow-up, and a bolstered regimen. These 
recom mendations, which also have importance for the 
design of treatment programmes, need to be prospectively 
validated. The high capreomycin resistance is cause for 
concern since this antibiotic is the mainstay of regimens 
for the treatment of XDR tuberculosis that are used 
globally, and it has not previously been widely used in 
South Africa. The reasons are not known, but might 
partly indicate the unreliability of capreomycin-
susceptibility testing, or the potentially high cross-
resistance with aminoglycosides like kanamycin.34,35
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An additional key ﬁ nding was that 21 of 195 patients 
died before starting treatment, indicating that they had 
late access to treatment or inappropriate delivery of 
health services. Our data therefore emphasise the need 
to reduce delays in diagnosis and initiation of treatment 
through intensiﬁ ed case ﬁ nding,36 improve patient access 
and diagnostic reporting systems,25,37 and improve the 
rollout of rapid diagnostic tests for MDR and XDR 
tuberculosis.38 Because existing nucleic acid ampliﬁ cation 
tests are not eﬃ  cient enough in smear-negative cases,38 
application of rapid drug-sensitivity testing to all smear-
positive patients would be rational at ﬁ rst presentation. A 
favourable cost-beneﬁ t analysis of such an approach is 
supported by mathematical models.39 Development and 
validation of alternative methods that could be useful for 
detection of sputum-smear-negative tuberculosis are also 
urgently needed.40,41
Our data showed a high incidence of adverse events 
associated with drugs used for the treatment of XDR 
tuberculosis. The most serious adverse eﬀ ects were 
caused by capreomycin-associated renal dysfunction, 
which can occur at any time during the course of 
treatment; thus monitoring of capreomycin-based 
regimens, even in resource-poor settings is mandatory.
Limitations of our ﬁ ndings are due to the retrospective 
study design. We have tried to reduce bias by excluding 
patients with incomplete treatment and microbiological 
data, by excluding individuals who had culture converted 
before initiation of treatment for XDR tuberculosis, by 
crosschecking patients against clinical and laboratory 
databases, and by using methods to ensure data integrity. 
Selection bias, particularly in the HIV-infected subgroup, 
might have led to an underestimate of the true number of 
deaths since survivors would have had an increased 
likelihood of being included in our study. Since all cases of 
XDR tuberculosis were detected passively, we are likely to 
have missed many patients who had remained undiagnosed 
or died before susceptibility testing, and patients who did 
not have access to health care, or in whom appropriate 
susceptibility testing was not undertaken because of 
capacity limitations. Nevertheless, the proportion of deaths 
did not diﬀ er in centres with a high urbanised population 
and easy medical access (Gauteng and Western Cape) 
compared with those that had high rural populations with 
restricted access (Eastern Cape and Northern Cape). 
Although we noted a survival beneﬁ t with moxiﬂ oxacin, 
the number of patients treated with this drug was small, 
and we could not correlate outcomes with quinolone-
speciﬁ c resistance proﬁ les because of the lack of speciﬁ c 
data for drug-susceptibility testing. Our ﬁ ndings are only 
generalisable to a resource-poor high HIV prevalence 
setting like South Africa. Outcomes in settings with low 
HIV prevalence and in those that are even more severely 
resource-constrained might be diﬀ erent.
Since patients with XDR tuberculosis have poor 
management outcomes in South Africa, prevention of 
this type of tuberculosis, and early detection and 
management of MDR and XDR tuberculosis, through 
strengthened programmes and laboratory capacity 
remain the priorities for areas that have high endemicity 
of tuberculosis and HIV/AIDS.
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